Abstract:Natural killer/T cell lymphoma (NKTCL) is an aggressive subtype of non-Hodgkin lymphoma that is rare overall but has a higher prevalence in Chinese and Hispanic populations. Recent sequencing efforts have improved the understanding of the disease and revealed a number of genes that may drive the pathogenesis of NKTCL. These efforts were largely limited by the number of cases studied. Based on previously reported whole exome sequencing data in NKTCL and other lymphoid malignancies and on the frequency and potential biological significance of the mutant, we designed a 334-gene panel and sequenced 105 NKTCLs. We characterized single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number alterations (CNAs) that may have pathogenic roles. Tumor DNA was isolated from 74 Chinese and 31 Hispanic NKTCL patients. For 7 of these, matched normal DNA was extracted from peripheral blood. The 334 genes in the custom panel were captured using the Agilent SureSelect platform, and the exons of these genes were sequenced on an Illumina HiSeq 2500 instrument. For cases without matched normal samples, we discriminated between somatic and germline variants with an in-house machine learning algorithm which is based on information of public variant databases, variant annotations, and sequencing statistics, and followed by manual inspection. CNAs were determined based on the untargeted sequences using an R package, CopywriteR . We identified a total of 479 SNVs and 113 indels in 155 genes in 102 out of 105 patients. Mutations in STAT3 and JAK3 were identified in 30% and 7% of the cases, respectively. The hotspot mutations Y640F, S614R, and G618R in the SH2 domain of STAT3 and A573V of the JH2 domain of JAK3 were observed in most of these cases. 46% of the cases harbored one or more mutations in epigenetic regulators ARID1A , EP300 , MLL2 , MLL3 , and TET2 . Transcription co-repressors BCOR and NCOR2 were mutated in 25 of the cases. 13% of the cases contained mutations in HLA-A or CIITA , most of which were inactivating, suggesting possible defects in immune surveillance. DDX3X and TP53 mutations were detected in 19% and 10% of the cases, respectively. TP53 mutations were mutually exclusive with mutations in DDX3X and, except for one case, with STAT3 also. MGA mutations, which were present in 12% of the cases, were usually concurrent with STAT3 mutations. The mutational profiles of Chinese and Hispanic cases were similar, and only CD58 mutations were significantly more common in Hispanic patients (p=0.03). Comparison between NKTCL with localized and systemic presentation demonstrated that CCR7 was mutated more frequently in systemic cases (p=0.02). Prognostic analysis identified EP300 mutations as a potential marker for poorer survival (p=0.01). Frequent copy loss on chromosome 6q was observed and PRDM1 , which is present on 6q, was mutated in 10% of the cases. In summary, we identified the profile of mutated genes in a large series of NKTCL. Most of the genes have been previously reported to be mutated in NKTCL, but the frequencies for some of the mutants were quite different. Interestingly, the mutational profiles of NKTCL in Chinese and Hispanic patients were very similar despite the geographic differences. Mutations leading to abnormal activation of the JAK-STAT3 pathway and abnormal chromatin modification were highly prevalent. BCOR , DDX3X and TP53 mutations were also frequent. Variants in CCR7 and EP300 were potential markers for systemic disease and poor prognosis, respectively. Disclosures No relevant conflicts of interest to declare.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Frequent Activating Mutations of JAK-STAT Pathway Genes in Natural Killer Cell Lymphomas

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Pathological features and prognosis of natural killer cell lymphoma and leukemia

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

Genomic Profiling Identifies Distinct Genetic Subtypes in Extra-Nodal Natural Killer/t-Cell Lymphoma.

Expression of CD6 in Aggressive NK/T-cell Neoplasms and Assessment as a Potential Therapeutic Target: A Bone Marrow Pathology Group Study

Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations

Molecular pathogenic pathways in extranodal NK/T cell lymphoma

NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm

Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review

[Molecular profiling of myeloid/natural killer (NK) cell precursor acute leukemia]

Driver Mutations Affecting Natural Killer/T Cell Lymphoma

Additional File 2 of Aberrant JAK-STAT Signaling-Mediated Chromatin Remodeling Impairs the Sensitivity of NK/T-cell Lymphoma to Chidamide

Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia

Aberrant JAK-STAT Signaling-Mediated Chromatin Remodeling Impairs the Sensitivity of NK/T-cell Lymphoma to Chidamide.

A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance

Mutational characteristics of extranodal NK/T-cell lymphoma analyzed in relation to clinical prognostic indices

Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia